A Phase One, Single Dose, Randomized, Open-label, Two-period, Two-sequence, Crossover, Absolute Bioavailability Study Of Glasdegib (Pf-04449913) In Healthy Volunteers

Trial Profile

A Phase One, Single Dose, Randomized, Open-label, Two-period, Two-sequence, Crossover, Absolute Bioavailability Study Of Glasdegib (Pf-04449913) In Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Glasdegib (Primary) ; Glasdegib (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Colorectal cancer; Haematological malignancies; Myelodysplastic syndromes; Myelofibrosis; Non-small cell lung cancer
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 18 Sep 2017 Planned End Date changed from 10 Nov 2017 to 30 Oct 2017.
    • 18 Sep 2017 Planned primary completion date changed from 18 Oct 2017 to 6 Oct 2017.
    • 11 Sep 2017 Planned End Date changed from 17 Nov 2017 to 10 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top